



Allergic Airway Disease Prevents Lethal Synergy of Influenza A Virus-*Streptococcus pneumoniae* Coinfection

Sean Roberts,^a Sharon L. Salmon,^a Donald J. Steiner,^a Clare M. Williams,^a Dennis W. Metzger,^a Yoichi Furuya^a

^aDepartment of Immunology and Microbial Disease, Albany Medical College, Albany, New York, USA

ABSTRACT Fatal outcomes following influenza infection are often associated with secondary bacterial infections. Allergic airway disease (AAD) is known to influence severe complications from respiratory infections, and yet the mechanistic effect of AAD on influenza virus-*Streptococcus pneumoniae* coinfection has not been investigated previously. We examined the impact of AAD on host susceptibility to viral-bacterial coinfections. We report that AAD improved survival during coinfection when viral-bacterial challenge occurred 1 week after AAD. Counterintuitively, mice with AAD had significantly decreased proinflammatory responses during infection. Specifically, both CD4⁺ and CD8⁺ T cell interferon gamma (IFN- γ) responses were suppressed following AAD. Resistance to coinfection was also associated with strong transforming growth factor β 1 (TGF- β 1) expression and increased bacterial clearance. Treatment of AAD mice with IFN- γ or genetic deletion of TGF- β receptor II expression reversed the protective effects of AAD. Using a novel triple-challenge model system, we show for the first time that AAD can provide protection against influenza virus-*S. pneumoniae* coinfection through the production of TGF- β that suppresses the influenza virus-induced IFN- γ response, thereby preserving antibacterial immunity.

IMPORTANCE Asthma has become one of the most common chronic diseases and has been identified as a risk factor for developing influenza. However, the impact of asthma on postinfluenza secondary bacterial infection is currently not known. Here, we developed a novel triple-challenge model of allergic airway disease, primary influenza infection, and secondary *Streptococcus pneumoniae* infection to investigate the impact of asthma on susceptibility to viral-bacterial coinfections. We report for the first time that mice recovering from acute allergic airway disease are highly resistant to influenza-pneumococcal coinfection and that this resistance is due to inhibition of influenza virus-mediated impairment of bacterial clearance. Further characterization of allergic airway disease-associated resistance against postinfluenza secondary bacterial infection may aid in the development of prophylactic and/or therapeutic treatment against coinfection.

KEYWORDS *Streptococcus pneumoniae*, coinfection, influenza, interferon gamma

Both *Streptococcus pneumoniae* and influenza virus infections are leading causes of morbidity and mortality worldwide. A synergistic relationship between these two pathogens is well documented, as the majority of deaths during the 1918 influenza pandemic were attributed to secondary complications from *S. pneumoniae* infection (1, 2). Recent studies have begun to address why influenza patients become more susceptible to secondary bacterial infections (3–10), but we are far from having a complete understanding of these superinfections. Even less understood are how we can prevent increased susceptibility and what immune responses are required for protection.

The effect of asthma on mucosal immunity against respiratory pathogens has not been adequately addressed. During the influenza pandemic of 2009, asthma was the most common risk factor associated with morbidity among patients hospitalized with

Citation Roberts S, Salmon SL, Steiner DJ, Williams CM, Metzger DW, Furuya Y. 2019. Allergic airway disease prevents lethal synergy of influenza A virus-*Streptococcus pneumoniae* coinfection. *mBio* 10:e01335-19. <https://doi.org/10.1128/mBio.01335-19>.

Editor Keith P. Klugman, Emory University

Copyright © 2019 Roberts et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Yoichi Furuya, furuyay@amc.edu.

Received 22 May 2019

Accepted 28 May 2019

Published 2 July 2019

influenza (11). Interestingly, although asthma was associated with a higher hospital admission rate during influenza, hospitalized asthmatics were less likely to develop severe disease or to die than nonasthmatics (12, 13). It is possible that in the clinical setting, other factors, such as earlier hospital admission due to asthma exacerbation and the preadmission use of inhaled corticosteroids, positively influenced the disease outcome in asthmatic patients during the 2009 influenza pandemic (12). In addition, we recently reported using a mouse model of allergic airway disease (AAD) followed by influenza virus infection that AAD can be either beneficial or detrimental depending on the timing of viral and allergic challenge (14, 15). However, the susceptibility of AAD mice was assessed in the absence of secondary bacterial infection. As mentioned above, secondary bacterial infection is an important cause of mortality and morbidity during influenza pandemics.

In this work, we examined the influence of AAD on viral-bacterial coinfections, an approach that has not been documented previously. Our results demonstrate that ovalbumin (OVA)- or house dust mite (HDM)-mediated AAD confers resistance against influenza-*S. pneumoniae* coinfection in a mouse model. Counterintuitively, preceding AAD was associated with suppressed influenza-induced inflammation, and protection was dependent upon AAD-induced transforming growth factor β (TGF- β) production.

RESULTS

Allergic airway disease confers protection against postinfluenza secondary bacterial infection. To investigate the impact of AAD on viral-bacterial coinfection, we developed a triple-challenge mouse model of AAD, primary influenza infection, and secondary bacterial infection (Fig. 1A). Using this model, it was first established that influenza H1N1 A/California/4/2009 (CA04) virus-infected, non-AAD mice had defective A66.1 pneumococcal clearance at day 1 after bacterial infection (Fig. 1B), an observation consistent with our previous publications (4, 10, 16–18) and those of others (5–7, 9, 19, 20). In contrast, bacterial burden was undetectable in coinfecting OVA-AAD mice and was comparable to that in control mice that were infected with *S. pneumoniae* alone (Fig. 1B). However, no differences in viral burden were observed in non-AAD versus OVA-AAD mice (Fig. 1C). Survival analysis showed that coinfection was lethal in non-AAD mice but not in OVA-AAD mice (Fig. 1D). This enhanced survival was not unique to the CA04 and A66.1 challenge strains, as OVA-AAD also provided protection against coinfection involving H1N1 A/Puerto Rico/8/1934 (PR8) viral or D39 bacterial strains (Fig. 1E and F). Additionally, OVA-AAD had a positive, albeit not statistically significant, effect on survival during secondary methicillin-resistant *Staphylococcus aureus* (MRSA) infection (Fig. 1G). The improved survival against viral-bacterial coinfection was also not dependent on the order of viral and bacterial infections, as OVA-AAD mice were also resistant to bacterial-viral coinfection (see Fig. S1 in the supplemental material). Consistent with the OVA-AAD model, HDM-AAD mice were also resistant to postinfluenza secondary bacterial challenge (Fig. S2). Importantly, the C57BL/6 mouse strain likewise exhibited improved survival during viral-bacterial coinfection following induction of OVA-AAD (Fig. S3). Thus, the positive effect of AAD was not restricted to a particular mouse strain. Based on these results, we conclude that AAD mice are resistant to influenza-bacterial coinfection and that this resistance is due to intact bacterial clearance.

AAD mice have reduced inflammatory cytokine responses during infection. AAD is a predominantly T helper 2 (Th2) cell-driven disease, and it is widely recognized that Th2-type cytokines play a critical role in initiating and amplifying the inflammatory response during AAD (21). Given that Th2-type cytokine production during influenza infection is linked to asthma exacerbation (22), we investigated if infection superimposed on AAD mice would have an additive or synergistic effect on inflammation (Fig. 2A and Fig. S4A). As expected, in the absence of infection, Th2- but not Th1-type cytokines were highly upregulated at day 0 after the last allergen inoculation (Fig. S4B). By day 7 after the last HDM challenge, the levels of all cytokines were below the limit of detection (Fig. S4B). In the presence of viral-bacterial coinfection, both Th1-type and




FIG 1 AAD mice are resistant to influenza-*S. pneumoniae* coinfection. (A) Schematic diagram of the OVA-induced AAD and influenza-*S. pneumoniae* (*S.p*) coinfection protocol. (B) BALF was harvested, and bacterial burden was assessed 1 day after *S. pneumoniae* A66.1 infection ($n = 4$ to 5 mice/group). The horizontal dotted line is the limit of detection. (C) The CA04 viral burden in BALF was assessed 1 day after secondary bacterial challenge by a standard plaque assay ($n = 5$ mice/group). The dotted line is the limit of detection. (D to F) OVA-AAD and non-AAD mice were singly infected or coinfecting with 10 PFU of CA04 or PR8 and 2×10^2 CFU of *S. pneumoniae* A66.1 or 1.5×10^4 CFU of *S. pneumoniae* D39. The vertical dotted line indicates bacterial infection. (G) Non-AAD and OVA-AAD mice were coinfecting with 10 PFU of CA04 and 1.7×10^8 CFU of MRSA. Infected mice were monitored for survival for 20 days ($n = 3$ to 13 mice). The vertical dotted line indicates bacterial infection. **, $P < 0.01$; ***, $P < 0.001$.

Th2-type cytokines were highly upregulated in non-AAD mice (Fig. 2B and Fig. S4C). In contrast, with the exception of interleukin-5 (IL-5), these cytokine responses were significantly reduced in OVA- and HDM-AAD mice. Recent studies have demonstrated that influenza-induced inflammatory cytokines are central mediators of immune suppression after influenza infection (4–6, 8, 9, 23–25). The altered inflammatory response




FIG 2 Cytokine responses are suppressed in AAD mice. (A) Experimental setup. (B) Pulmonary cytokine levels in WT BALB/c mice were quantified day 1 after secondary bacterial challenge ($n = 4$ to 10 mice/group). *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$; ****, $P < 0.0001$.

during influenza infection may explain why AAD mice were protected against secondary bacterial infection.

AAD suppresses detrimental IFN- γ responses. Interferon gamma (IFN- γ) has been implicated in influenza virus-induced immune suppression during secondary *S. pneumoniae* infection (4, 16, 26, 27). We therefore measured pulmonary IFN- γ protein concentrations. IFN- γ responses to viral single infection or viral-bacterial coinfection were significantly suppressed in AAD mice (Fig. 3A). In agreement with IFN- γ protein levels in bronchoalveolar lavage fluid (BALF), numbers of IFN- γ -positive (IFN- γ^+) T cells were also suppressed in AAD mice (Fig. 3B and Fig. S5A). Similarly, reduced granzyme B-positive (Gzmb $^+$) T cell responses were observed in AAD mice (Fig. S5B). We next investigated the potential roles of IFN- γ in our triple-challenge model of AAD and coinfection. IFN- $\gamma^{-/-}$ but not non-AAD wild-type (WT) mice were protected against coinfection (Fig. 3C and D and Fig. S5C), consistent with previous reports (4, 16). IFN- γ deficiency had no effect on the survival of AAD mice (Fig. 3C and D and Fig. S5). These observations suggest that while IFN- γ exerts detrimental effects on non-AAD mice during coinfection, it does not play a protective role in AAD mice. Consistent with the survival data, IFN- γ deficiency prevented inhibition of A66.1 and D39 bacterial clearance in coinfecting non-AAD mice (Fig. 3E and F). The protected IFN- $\gamma^{-/-}$ non-AAD mice still expressed higher levels of various cytokines than did IFN- $\gamma^{-/-}$ AAD mice (Fig. 3G), suggesting that IFN- γ plays an important role in predisposing the host to secondary bacterial infections. Taken together, these data suggest that AAD mice were protected against secondary bacterial challenge due to suppression of IFN- γ responses that otherwise disabled antibacterial immunity. To directly demonstrate that suppression of IFN- γ responses was responsible for resistance against secondary bacterial challenge in AAD mice, we treated AAD mice intranasally (i.n.) with recombinant IFN- γ to increase pulmonary IFN- γ levels during coinfection (Fig. 4A). Exogenous IFN- γ significantly impaired early bacterial clearance in AAD mice (Fig. 4B and C). Therefore, the protective mechanism that exists in AAD mice may entail inhibition of detrimental IFN- γ responses.




FIG 3 Detrimental IFN- γ is suppressed during infection in AAD mice. (A) IFN- γ levels in BALF samples harvested 1 day after secondary bacterial challenge ($n = 4$ to 10 mice/group). (B) Numbers of pulmonary IFN- γ ⁺ CD4⁺ or CD8⁺ T cells at day 8 after influenza infection ($n = 4$ to 5 mice/group). (C and D) Survival analysis of WT BALB/c and IFN- γ ^{-/-} mice singly infected or coinfecting with CA04 and D39 (C) or A66.1 (D) ($n = 4$ to 14 mice/group). Vertical dotted lines indicate bacterial infection. (E and F) Pulmonary bacterial burdens 1 day after single infection or coinfection in WT BALB/c or IFN- γ ^{-/-} mice ($n = 3$ to 5 mice/group). Horizontal dotted lines indicate the limit of detection. (G) Pulmonary cytokine levels in IFN- γ ^{-/-} mice at day 1 after secondary bacterial challenge ($n = 7$ to 9 mice/group). The dotted line is the limit of detection. *, $P < 0.05$; **, $P < 0.01$; ****, $P < 0.0001$; NS, not significant.

Alveolar macrophage-mediated bacterial clearance is intact in AAD mice. Since innate immune cells are involved in early bacterial clearance, we next characterized the pulmonary cellular environment to elucidate the role of innate immune cells in AAD-mediated resistance to secondary bacterial infection. Flow cytometric analysis




FIG 4 IFN- γ treatment compromises bacterial clearance in AAD mice. (A) Amount of IFN- γ in BALF 4 h after secondary bacterial challenge. Mice were i.n. treated with PBS or recombinant IFN- γ prior to a bacterial infection ($n = 5$ mice/group). (B and C) Pulmonary bacterial load, expressed as CFU per milliliter of BALF (B) or as a percentage of the input (C), 4 h after secondary bacterial challenge ($n = 5$ mice/group). The dotted line is the limit of detection. *, $P < 0.05$; ***, $P < 0.001$; ****, $P < 0.0001$.

showed that on day 7 after AAD, monocyte numbers were marginally increased in uninfected OVA-AAD mice (Fig. S6 and Fig. S7). However, upon CA04 infection, the monocyte numbers were higher in non-AAD mice than in OVA-AAD mice. Similarly, increased numbers of neutrophils were observed in CA04-infected non-AAD mice. In contrast, levels of eosinophils were consistently higher in OVA-AAD mice on day 7 after AAD and day 8 after CA04 infection. However, eosinophil depletion using anti-IL-5 neutralizing monoclonal antibody (mAb) did not impact the survival of coinfecting AAD mice (data not shown), thus eliminating the role of eosinophils in our observed protection in AAD mice. Finally, no striking differences in alveolar macrophage numbers were observed among non-AAD and OVA-AAD mice before or after CA04 infection. Based on these flow cytometry analyses, we conclude that AAD does not increase pulmonary cell numbers that may contribute to the resistance of AAD mice.

We have previously reported that alveolar macrophages play an important role in early bacterial clearance (4, 28, 29). Indeed, depletion of alveolar macrophages during coinfection of AAD mice significantly reduced survival (Fig. 5A and Fig. S8A). Consistent with the survival data, alveolar macrophage depletion significantly increased the bacterial burden in coinfecting OVA-AAD mice (Fig. 5B). It is important to note that the bacterial burden measured in clodronate-treated AAD mice was comparable to that in non-AAD mice treated with clodronate. This suggests that the observed protection in AAD mice was dependent on alveolar macrophages. The data described above demonstrated that IFN- γ played a detrimental role during coinfection and that AAD suppressed this response. We next determined if macrophages are the primary target of IFN- γ -mediated immune suppression by utilizing mice insensitive to IFN- γ (MIIG) (30). MIIG mice have a truncation in the IFN- γ receptor gene in CD68⁺ cells, rendering macrophages nonresponsive to IFN- γ . IFN- γ signaling deficiency in macrophages significantly improved the survival of coinfecting non-AAD mice but had no deleterious effect on AAD mice (Fig. 5C and D and Fig. S8B). Similarly, IFN- γ signaling deficiency in macrophages resulted in fewer pulmonary bacteria in non-AAD mice although not to a statistically significant extent (Fig. 5E). We next assessed whether the difference in bacterial clearance was due to differences in macrophage-dependent phagocytosis. We measured the expression levels of mannose receptor (MR), a pattern recognition receptor that mediates nonopsonic phagocytosis by macrophages (31). CA04 infection significantly reduced mannose receptor expression in non-AAD mice (Fig. 5F to H). This reduction was absent in IFN- γ ^{-/-} mice, indicating that influenza-induced IFN- γ mediates the downregulation of mannose receptor expression. OVA-AAD mice also maintained baseline expression of mannose receptor following CA04 infection, likely due to the absence of IFN- γ responses. Consistent with these phenotypic data, an *in vivo* phagocytosis assay revealed that alveolar macrophages of OVA-AAD mice maintained intact phagocytic capacity during influenza infection, while non-AAD alveolar macro-




FIG 5 The influenza-induced defect in alveolar macrophages is absent in AAD mice. (A and B) CA04-infected mice were i.n. treated with clodronate liposomes (L-Clon) or PBS liposomes (L-PBS) on day 7 after influenza infection. CA04-infected, liposome-treated mice were coinfecting with A66.1 on day 8 after influenza infection. (A) Mice were monitored for survival ($n = 5$ to 8 mice/group). The vertical dotted line indicates bacterial infection. (B) Additional mice were euthanized for assessment of bacterial burden ($n = 8$ mice/group). The limit of detection was 1×10^2 CFU/ml. (C and D) WT and MIIG mice were OVA treated and coinfecting as described in the legend of Fig. 1A, using A66.1 (C) or D39 (D) ($n = 5$ to 9 mice/group). Vertical dotted lines indicate bacterial infection. (E) Bacterial numbers in BALF harvested at day 1 after secondary bacterial infection ($n = 4$ to 10 mice/group). The limit of detection was 1×10^2 CFU/ml. (F to H) Flow cytometric analysis of mannose receptor (MR) expression on BALF CD11c^{hi} CD11b^{lo} Ly6G⁻ cells. (F to H) Representative histograms (F), median fluorescence intensity (MFI) (G), and fold change in MFI over the PBS control (H) of MR expression at day 8 after CA04 infection ($n = 5$ to 7 mice/group). (I and J) Mock-infected or CA04-infected mice were i.n. inoculated with FITC-labeled latex beads on day 8 after influenza infection, and BALF cells were harvested for flow cytometric analysis. Representative histograms (Continued on next page)

phages had reduced bead uptake after CA04 infection (Fig. 5I and J). Furthermore, to evaluate the influence of influenza virus on *S. pneumoniae* killing activities, BALF cells were harvested on day 8 after CA04 infection and incubated with live bacteria. Bacterial burdens in culture supernatants showed that BALF cells from OVA-AAD mice can better clear *S. pneumoniae* *in vitro* than BALF cells from non-AAD mice (Fig. 5K). Collectively, these data suggest that influenza virus disables antibacterial functions of alveolar macrophages via IFN- γ signaling and that this detrimental immune pathway is absent in AAD mice due to suppression of IFN- γ responses.

Correlation between upregulation of anti-inflammatory TGF- β 1 and absence of detrimental IFN- γ during AAD. We previously showed that TGF- β promotes survival of AAD mice during lethal influenza infection (14). To investigate if TGF- β also plays a role during coinfection, we determined whether there was a correlation between upregulation of TGF- β , suppression of IFN- γ , and improved survival. For this, AAD mice were examined at two time points after induction of AAD: week 1 versus week 6 after AAD (Fig. 6A and Fig. S9A). Consistent with our previous report (14), pulmonary TGF- β 1 expression was highly upregulated at week 1 after AAD but returned to baseline levels at week 6 (Fig. 6B and Fig. S9B). A slight increase in TGF- β 2 expression was observed in HDM-AAD mice at week 6 but not in OVA-AAD mice. TGF- β 3 levels were unchanged in both OVA- and HDM-AAD mice. Following influenza infection, TGF- β 1 levels were comparable between non-AAD and OVA-AAD mice (Fig. 6C). Next, AAD mice were infected with CA04 virus at week 1 or 6 for IFN- γ analysis. Robust pulmonary IFN- γ ⁺ T cell responses were observed in non-AAD mice as well as in week 6 post-OVA-AAD mice but were absent in week 1 post-OVA-AAD mice (Fig. 6D and E). These flow cytometry data were confirmed by a cytokine enzyme-linked immunosorbent assay (ELISA): CA04 infection elicited strong BALF IFN- γ expression in non-AAD mice and week 6 post-OVA-AAD mice but not in week 1 post-OVA-AAD mice (Fig. 6F). As expected, AAD-mediated protection against coinfection was completely lost at week 6 (Fig. 6G and Fig. S9C). This loss of protection correlated with increased bacterial burden but not viral burden (Fig. 6H). The above-described data indicate that TGF- β 1 is responsible for the suppressed IFN- γ cytokine milieu in the lungs of AAD mice, which in turn decreases susceptibility to secondary bacterial infections after influenza infection.

TGF- β RII signaling mediates suppression of IFN- γ and protection against secondary bacterial challenge. To determine whether there was a causal relationship between the above-described observations, conditional TGF- β receptor II (TGF- β RII)-deficient mice were used. Loss of TGF- β RII during coinfection significantly increased the expression of various cytokines, including IFN- γ , in OVA-AAD mice (Fig. 7A). While TGF- β RII deficiency had a minimal impact on survival during single infection, a significant reduction in survival of coinfecting AAD mice was observed (Fig. 7B and Fig. S9D). TGF- β RII deficiency also caused a significant increase in the bacterial burden during coinfection in OVA-AAD mice (Fig. 7C), which likely accounts for the observed mortality.

DISCUSSION

This is the first study to examine the impact of AAD on viral-bacterial coinfection, using a novel triple-challenge mouse model of AAD, primary influenza infection, and secondary *S. pneumoniae* infection. Here, we provide evidence for a novel finding in AAD mice whereby the host becomes resistant to postinfluenza bacterial infection. We conclude that AAD can transiently prevent viral-bacterial lethal synergy and thereby provide a survival advantage during secondary bacterial infection.

Using mice with a conditional deletion of TGF- β RII, we identified TGF- β as a central mediator of the observed protection. The data strongly suggest, however, that TGF- β is not an effector cytokine that directly or indirectly facilitates bacterial clearance.

FIG 5 Legend (Continued)

(I) and MFI (J) of the FITC signal on BALF CD11c^{hi} CD11b^{lo} Ly6G⁻ cells are shown. (K) Bacterial burden *in vitro* after 4 h of incubation with 5×10^4 BALF cells at an MOI of 1 CFU of A66.1/cell. BALF cells were harvested from non-AAD and OVA-AAD mice at day 8 after influenza infection ($n = 4$ to 5 mice/group). *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$; ****, $P < 0.0001$.




FIG 6 Suppressed IFN- γ responses are inversely associated with TGF- β 1 responses. (A) Diagram depicting the timeline of OVA treatment and viral-bacterial coinfection. (B) TGF- β levels in BALF at week 1 or 6 after OVA challenge ($n = 4$ to 5 mice/group). (C) TGF- β 1 levels in BALF in PBS-treated or CA04-infected mice at day 8 after influenza infection ($n = 9$ mice/group). (D and E) Flow cytometric analysis of IFN- γ ⁺ CD4⁺ T cells (D) and IFN- γ ⁺ CD8⁺ T cells (E) in BALF at day 8 after influenza infection ($n = 5$ to 8 mice/group). (F) Amount of IFN- γ in BALF at day 8 after influenza infection ($n = 5$ to 8 mice/group). (G) Survival analysis of OVA-AAD mice coinfecting at week 1 or 6 after OVA challenge ($n = 5$ mice/group). The vertical dotted line indicates bacterial infection. (H) Viral and bacterial loads in OVA-AAD mice coinfecting at week 1 or 6 after OVA challenge ($n = 5$ mice/group). The dotted line is the limit of detection. **, $P < 0.01$; ***, $P < 0.001$; ****, $P < 0.0001$.

Rather, TGF- β reverses or prevents influenza virus-induced inhibition of pulmonary bacterial clearance. In support of this, i.n. treatment with recombinant mouse IFN- γ renders AAD mice unable to effectively control bacterial replication despite having high levels of TGF- β . Additionally, AAD-associated protection was lost following depletion of alveolar macrophages, a primary effector cell type responsible for early bacterial clearance. It is important to note that the bacterial burden measured in macrophage-depleted AAD mice was comparable to that in macrophage-depleted or -undepleted non-AAD mice. This suggests that the observed protection in AAD mice is dependent on intact alveolar macrophages and that AAD does not enhance other antibacterial pathways that could compensate for the loss of macrophages. In support of this, numbers of other phagocytic cell types, such as monocytes and neutrophils, were found to be reduced in AAD mice.




FIG 7 TGF- β mediates resistance of AAD mice against secondary bacterial challenge. *TβRII^{fl/fl}-Cre* mice and wild-type littermates were OVA treated and coinfectd as described in the legend of Fig. 1A. (A) Cytokine analysis at day 1 after secondary bacterial challenge ($n = 7$ to 9 mice/group). GM-CSF, granulocyte-macrophage colony-stimulating factor. (B) Survival analysis of mice with viral infection, bacterial infection, or coinfection (4 to 10 mice/group). The vertical dotted line represents PBS or A66.1 challenge. (C) Bacterial burden at day 1 after secondary bacterial challenge ($n = 7$ to 9 mice/group). The dotted line is the limit of detection. *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$.

It has been shown that proinflammatory cytokine responses directed against influenza viruses are a key driver of secondary bacterial infections. In particular, IFN- γ appears to play a central role in suppressing antibacterial immunity during influenza infection (23). This detrimental IFN- γ response was found to be significantly suppressed during infection of AAD mice. However, deletion of TGF- β RII signaling unleashed IFN- γ responses in AAD mice. This was associated with the outgrowth of *S. pneumoniae* and the loss of a survival advantage in AAD mice. Based on these observations, it was concluded that AAD-induced TGF- β promotes survival during coinfection by suppressing detrimental IFN- γ responses. Furthermore, we investigated the downstream deleterious effects of IFN- γ signaling. The use of MIIG mice provided evidence that influenza-induced IFN- γ directly interacts with phagocytic cells to suppress antibacterial immunity. Thus, we have identified the protective immune pathway triggered by AAD: transiently heightened levels of TGF- β result in suppression of IFN- γ expression,

and this in turn prevents IFN- γ -alveolar macrophage interactions that would otherwise inhibit antibacterial immunity and cause enhanced susceptibility to secondary bacterial infections.

TGF- β is known to be directly activated by microbial enzymes such as neuraminidase (NA) of influenza A virus (32–35) and of *S. pneumoniae* (36). One group recently reported that influenza A virus NA enhances *in vitro* bacterial adherence to cultured A549 human lung carcinoma cells, in a TGF- β signaling-dependent manner (32). Therefore, it was hypothesized that upregulation of TGF- β during influenza infection promotes secondary bacterial infection *in vivo*. Indeed, the same group reported that primary influenza infection enhances group A *Streptococcus* bacterial burden in the lungs of WT mice but not in the lungs of mice deficient in TGF- β signaling (32). Whether influenza virus NA-activated TGF- β could play a similar role in influenza-*S. pneumoniae* coinfection is unknown. Of note, in our model, TGF- β activation was triggered by AAD and preceded influenza infection. Thus, activation of TGF- β prior to influenza infection may be necessary to exert its protective effect during viral-bacterial coinfection. Our findings also suggest that the benefit of suppressing IFN- γ by AAD-induced TGF- β outweighs any potential detrimental effect of TGF- β -mediated bacterial adherence for coinfections involving *S. pneumoniae*.

Given that AAD-induced TGF- β 1 responses were transient, it was not surprising that AAD-mediated protection was also transient. By week 6 after AAD, TGF- β 1 levels returned to baseline, and protection against coinfection was completely lost. Similar to our mouse model, TGF- β upregulation is inducible and transient in human asthmatics (37). One longitudinal clinical study demonstrated that the concentration of TGF- β 1 in BALF returns to baseline within 1 week after allergen exposure (38). Thus, it can be predicted that asthmatic episodes must precede viral infection for TGF- β to be upregulated and provide survival benefits against secondary bacterial infection. In support of this, Avila et al. (39) demonstrated that allergic subjects with experimental rhinovirus infection exhibit a significantly delayed onset of cold symptoms and a reduced duration of illness if high-dose allergen exposure preceded viral inoculation.

Consistent with our previous publication (14), this study also showed that pulmonary viral load was not exacerbated by AAD. Other investigators that have relied on a comorbidity mouse model of asthma and influenza have also reported that a preceding acute allergen challenge does not impair viral clearance (40–44). In fact, it was shown that AAD reduces pulmonary influenza viral burden (40–44), although the proposed immunological mechanisms are inconsistent among various studies. In support of these findings, a recent human study using an *ex vivo* influenza infection model of bronchial tissue explants demonstrated that viral load was reduced in bronchial biopsy specimens derived from asthmatic subjects (45). Thus, our finding that viral clearance was not impeded by prior AAD is consistent with the literature. Of note, cytolytic T cell responses were detected in our mouse model of AAD following influenza infection. It is likely that detectable, albeit reduced, levels of antiviral GzmB⁺ T cells were sufficient to clear the viral infection given that a low dose of influenza virus (10 PFU) was used in our coinfection model.

Suppression of not only IFN- γ but also the cytolytic protein GzmB in AAD mice suggests that a preceding AAD leads to a general inhibition of T cell effector functions. Our results indicate that TGF- β is playing a role in suppressing effector functions of T cells in AAD mice. This hypothesis is based on observations that deletion of TGF- β RII signaling significantly increased IFN- γ levels in the lungs of coinfecting AAD mice at day 9 after viral infection, a time point that corresponds to the peak of the T cell response in influenza-infected mice. Furthermore, intracellular staining revealed that the major sources of IFN- γ during coinfection are CD4⁺ and CD8⁺ T cells in susceptible non-AAD mice. The suppressive effects of TGF- β on T cells are well established in cancer immunology (46–49). Substantial evidence exists that TGF- β can directly regulate activation, proliferation, differentiation, and survival of T cells. TGF- β signaling in T cells is mediated by TGF- β RI and -II, and the eventual activation of downstream transcription factors, such as Smad, regulates the T cell phenotype (50). This pleiotropic cytokine can

also promote CD4⁺ regulatory T cell (Treg) responses. Whether the suppression of IFN- γ ⁺ T cell responses in AAD mice is a direct effect of TGF- β on effector T cells or of Treg induction remains to be elucidated.

Like CA04 viral infection, preexisting AAD also conferred protection in PR8 virus-infected mice against secondary *S. pneumoniae* infection. This observation suggests that our result was not due to a unique phenotype of the CA04 virus but rather reflected a general phenomenon associated with influenza A virus infection in AAD mice. Furthermore, CA04-infected AAD mice were also resistant to secondary methicillin-resistant *Staphylococcus aureus* infection. MRSA is an emerging bacterial pathogen associated with recent seasonal and pandemic influenza. Thus, our findings may have broad application to other secondary bacterial pathogens. A better understanding of the protective immune mechanisms that exist in AAD mice is a significant first step that could eventually lead to the development of immunomodulation strategies to ameliorate detrimental immune responses.

The long-standing dogma that asthma is a risk factor for severe influenza has been challenged by recent clinical studies. Veerapandian et al. (51) conducted a systematic literature review of clinical reports on asthmatic patients during the 2009 pandemic of H1N1 virus and confirmed that asthma was a risk factor for hospitalization. However, the same authors also concluded, based on an overwhelming amount of clinical data (12, 13, 52–59), that asthmatics were less likely to develop severe influenza, as defined as intensive care unit (ICU) admittance and/or death (51). Given that 29 to 55% of deaths during the 2009 H1N1 pandemic were due to complications from secondary bacterial infections (60–62), it is possible that less severe influenza outcomes among asthmatics are due to prevention of secondary bacterial infections. Nonetheless, no data are available to support or refute this prediction, since the majority of clinical studies into the role of asthma in infection severity have focused on single pathogens. Only a limited number of studies have investigated the potential interaction between asthma and viral-bacterial coinfection. For example, Kloepfer et al. (63) recently examined coinfection in school-age children with and without asthma and concluded that asthma is not a risk factor for rhinovirus-*S. pneumoniae* coinfection. Unfortunately, patient samples that were positive for other viruses were excluded from their analysis. Thus, whether asthma is a risk or protective factor for influenza-*S. pneumoniae* coinfection is currently unknown.

A lower threshold of hospitalization for asthmatics has been proposed to explain why asthma was associated with less severe outcomes among hospitalized patients. However, Myles et al. (12) concluded that there was not a lower threshold for hospital admission for asthmatic patients since asthmatic and nonasthmatic patients presented with pneumonia at the time of admission in equal proportions. It was also noted in that clinical report that asthmatics were in fact more likely to exhibit features of severe respiratory compromise at the time of hospital admission. Thus, the improved clinical outcomes of asthmatic patients are unlikely to be the result of milder illness at the time of hospital admission. The same authors further concluded that preadmission steroid use contributed to the association of asthma with less severe clinical outcomes; however, preadmission steroid use was found to be beneficial only in asthmatic patients but not in nonasthmatic patients. This suggests that the preadmission steroid is not inherently protective against influenza. In addition, the benefit of in-hospitalization systemic steroid therapy is controversial, as some recent studies reported that steroid administration results in higher incidences of hospital-acquired bacterial pneumonia and of mortality (64–67). Thus, it is plausible that the immunosuppressive effects of preadmission steroid use may have predisposed asthmatics to influenza infections, which would explain why asthma was found to be a risk factor for increased hospitalization due to influenza. We propose that future studies should investigate the role of corticosteroids, in the context of asthma, in influencing susceptibility to coinfections. Such studies could provide a definitive answer for the controversial role of corticosteroids in influenza-infected asthmatic patients.

While epidemiological data derived from the H1N1 pandemic of 2009 support our

current findings, caution is needed in extrapolating data from mice to human disease. Since mice do not naturally develop asthma, the applicability of mouse models of asthma has long been debated. Of particular concern are the lack of irreversible airway remodeling and the lack of chronicity in the acute asthma model (68, 69). As such, short-term models can be used to investigate the impact of severe acute allergic inflammation on subsequent respiratory infection but are inadequate for investigation of the relationship between chronic inflammation and host susceptibility to pulmonary pathogens. In an attempt to overcome some of the limitations of acute mouse models of asthma, a number of investigators have developed mouse models of chronic asthma by extending the period of allergen challenge (70–73). These chronic mouse models better mimic various features of human airway remodeling and therefore make it possible to study host susceptibility during the chronic phase of asthma in mice. The impact of chronic allergic inflammation on influenza-induced susceptibility to secondary bacterial infection is under investigation.

While informative epidemiological data are greatly lacking, it has been reported by various investigators that asthmatic patients exhibit defective type I IFN (IFN-I) and IFN-II responses during viral infections, as characterized *in vivo* and *ex vivo* (74–77). Coincidentally, numerous mouse studies of viral-bacterial coinfection have identified IFN-I and -II as mediators of heightened sensitivity to secondary bacterial challenges (4, 6, 8, 9, 16). Thus, if these cytokines are indeed responsible for predisposing the host to secondary bacterial infections in humans, it can be extrapolated that decreased levels of IFN-I and -II in asthmatic patients would confer some level of protection during coinfection. Further research will be needed to confirm our hypothesis on the role of asthma during viral-bacterial coinfection.

The synergistic mechanisms of viral-bacterial coinfections have been investigated by a number of researchers, with the ultimate goal of developing therapeutic approaches to prevent mortality and morbidity. Most, if not all, investigators have relied on a mouse model of primary influenza infection and secondary bacterial infections (4, 6–9, 19, 20, 78–80), with the principal aims of identifying detrimental immune responses in coinfecting mice and of understanding how influenza virus predisposes mice to secondary bacterial infections. The rationale behind this approach is that understanding the nature of the disadvantageous immune response may enable reversal of the immunocompromised state. In contrast, the present study focused on understanding protective elements of the immune response by examining mice that are resistant to secondary bacterial infections. Our data showing a remarkable resistance of AAD mice to coinfection were surprising and now offer a unique opportunity to understand a beneficial immune pathway that may render the host transiently resistant to secondary bacterial infections. To the best of our knowledge, a triple-challenge mouse model of asthma, primary influenza infection, and secondary pneumococcal infection has not been previously documented in the literature. Further characterization of AAD-associated resistance against viral-bacterial coinfection may aid in the development of prophylactic and/or therapeutic treatment against coinfection.

MATERIALS AND METHODS

Mice. Adult 6- to 8-week-old BALB/c and C57BL/6 mice were purchased from Charles River Laboratories through a contract with the National Cancer Institute. BALB/c IFN- $\gamma^{-/-}$ mice were obtained from Jackson Laboratories (Bar Harbor, ME). C57BL/6 mice with macrophages insensitive to IFN- γ (MIIG) were previously generated at Cincinnati Children's Hospital Medical Center (30). *T β RIII^{f/f}-Cre* mice were generated by crossing Floxed *T β RIII* (*T β RIII^{f/f}*) and *Ubc-CreERT2* (*Cre*) mice (14). To induce conditional deletion of *T β RIII*, mice were injected intraperitoneally (i.p.) with 2 mg of tamoxifen (Sigma-Aldrich) in corn oil (Sigma-Aldrich) once daily for five consecutive days. Mice were treated with tamoxifen prior to intranasal (i.n.) allergen challenge. Animal care and experimental protocols were in accordance with the NIH *Guide for the Care and Use of Laboratory Animals* (81) and were approved by the Institutional Animal Care and Use Committee at Albany Medical College (protocol number 17-03006).

A triple-challenge mouse model of AAD, primary influenza infection, and secondary *S. pneumoniae* infection. For the OVA-AAD model, mice were immunized i.p. twice with 10 μ g of OVA in 4 mg of aluminum hydroxide (General Chemical). The sensitized mice were anaesthetized with isoflurane and challenged i.n. with 100 μ g of OVA in phosphate-buffered saline (PBS) once daily for 5 days. For induction of HDM-AAD, mice were anaesthetized and i.n. treated with 50 μ g of HDM extract (*Dermatophagoides*

pteronysinus; Greer Laboratories) in PBS for three consecutive days every 3 weeks. Control non-AAD mice received 50 μ l PBS. The AAD or non-AAD mice were infected i.n. with 10 PFU of H1N1 A/California/4/2009 (CA04) virus or H1N1 A/Puerto Rico/8/1934 (PR8) virus and subsequently infected with 2×10^2 CFU of the *S. pneumoniae* serotype 3 A66.1 strain, 1.5×10^4 CFU of the *S. pneumoniae* serotype 2 D39 strain, or 2×10^8 CFU of methicillin-resistant *Staphylococcus aureus* (MRSA) strain USA300 at day 8 after influenza infection. Coinfection was routinely performed on week 1 after the last i.n. treatment, unless otherwise stated. This time point was chosen to minimize the unintended effects of i.n. PBS treatment while allowing investigation of the impact of AAD on host susceptibility to coinfection.

Pulmonary viral and bacterial burdens. Bronchoalveolar lavage fluid (BALF) was harvested by lavaging the lungs with 1 ml of PBS. Serial dilutions of cell-free BALF were added to MDCK cell monolayers and blood agar plates to enumerate viral PFU and bacterial CFU, respectively.

Cytokine analysis. Protein levels of IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, tumor necrosis factor alpha (TNF- α), and IFN- γ in cell-free BALF samples were analyzed using Bio-Plex mouse cytokine assays (Bio-Rad, Hercules, CA).

Flow cytometric analysis. The BALF cells were harvested in 1 ml of PBS. Live cells were enumerated based on trypan blue staining. Dead cells were labeled with fixable viability dye (FVD; eBioscience). Fc receptors were blocked by incubation with mouse 2.4G2 (Fc γ III/II receptor) antibody. Fc receptor-blocked cells were then stained with mixtures of anti-mouse surface antigen mAbs: Alexa Fluor 488-conjugated anti-CD11b (clone M1/70; BioLegend), brilliant violet 421-conjugated anti-Ly6C (clone HK1.4; BioLegend), fluorescein isothiocyanate (FITC)-conjugated anti-CD4 (clone GK1.5; BD Pharmingen), phycoerythrin (PE)-conjugated anti-SiglecF (clone E50-2440; BD Pharmingen), PE-Cy7-conjugated anti-CD8 (clone 53-6.7; BD Pharmingen), FITC-conjugated anti-macrophage mannose receptor (clone C068C2; BioLegend), allophycocyanin-conjugated anti-CD11c (clone N418; BioLegend), peridinin chlorophyll protein (PerCP)-Cy5.5-conjugated anti-CD11b (clone M1/70; eBioscience), PerCP-Cy5.5-conjugated anti-F4/80 (clone BM8; BioLegend), and PE-Cy7-conjugated anti-Ly6G (clone 1A8; BioLegend). Stained cells were analyzed using a FACSCanto flow cytometer.

Intracellular staining. To enumerate GzmB⁺ T cells and IFN- γ ⁺ T cells, 5×10^5 live BALF cells were restimulated with CA04 virus at a multiplicity of infection (MOI) of 1 (5×10^5 PFU/well) for 1 h, followed by 1 h of incubation with 10 μ g/ml of brefeldin A (Sigma). Cells were then stained with FVD, FcR blocked, and cell surface stained as described above. This was followed by incubation with BD fixation/permeabilization solution. After washing with BD Perm/Wash buffer, the cells were intracellularly stained with a PE-conjugated anti-IFN- γ mAb (clone XMG1.2; BioLegend) or FITC-conjugated anti-granzyme B mAb (clone NGZB; eBioscience). Rat IgG1-PE and rat IgG2a-FITC were used as isotype controls. Stained cells were quantitated using a FACSCanto flow cytometer.

In vivo phagocytosis assay. FITC-labeled fluorescent beads were i.n. administered on day 7 after influenza infection. BALF phagocytic cells were analyzed for FITC fluorescence intensity 24 h later by flow cytometric analysis.

In vitro bacterial burden assay. BALF cells were harvested from non-AAD and AAD mice on day 8 after CA04 infection and cultured in 96-well plates with *S. pneumoniae* A66.1 at an MOI of 1. The culture supernatants were harvested and added to blood agar plates to enumerate bacterial CFU.

Recombinant IFN- γ treatment. Mice were given 20 μ g of recombinant IFN- γ (BioLegend) i.n. on day 8 after influenza infection. One hour later, mice were i.n. inoculated with 10^5 CFU of D39 with or without 20 μ g of IFN- γ . The bacterial burden was then determined 4 h after D39 infection.

Statistical analysis. Results were analyzed using GraphPad Prism 6 software, with a *P* value of <0.05 considered to be statistically significant. Survival data were analyzed with a log rank (Mantel-Cox) test. All other data were analyzed by unpaired Student's *t* test with Welch's correction for comparison of two groups and by one- or two-way analysis of variance (ANOVA) with Bonferroni correction for comparison of multiple groups.

SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at <https://doi.org/10.1128/mBio.01335-19>.

FIG S1, PDF file, 0.04 MB.

FIG S2, PDF file, 0.04 MB.

FIG S3, PDF file, 0.02 MB.

FIG S4, PDF file, 0.05 MB.

FIG S5, PDF file, 0.04 MB.

FIG S6, PDF file, 0.1 MB.

FIG S7, PDF file, 0.04 MB.

FIG S8, PDF file, 0.03 MB.

FIG S9, PDF file, 0.05 MB.

ACKNOWLEDGMENTS

This work was supported by American Lung Association biomedical research grant RG-341974 to Y.F. and by U.S. NIH grant RO1 HL140496 to D.W.M. The funders had no

role in study design, data collection and interpretation, or the decision to submit the work for publication. We have no conflicting financial interests.

We have no conflict of interest.

REFERENCES

- Brundage JF, Shanks GD. 2008. Deaths from bacterial pneumonia during 1918-19 influenza pandemic. *Emerg Infect Dis* 14:1193–1199. <https://doi.org/10.3201/eid1408.071313>.
- Morens DM, Taubenberger JK, Fauci AS. 2008. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. *J Infect Dis* 198:962–970. <https://doi.org/10.1086/591708>.
- Metzger DW, Sun K. 2013. Immune dysfunction and bacterial coinfections following influenza. *J Immunol* 191:2047–2052. <https://doi.org/10.4049/jimmunol.1301152>.
- Sun K, Metzger DW. 2008. Inhibition of pulmonary antibacterial defense by interferon-gamma during recovery from influenza infection. *Nat Med* 14:558–564. <https://doi.org/10.1038/nm1765>.
- van der Sluijs KF, van Elden LJ, Nijhuis M, Schuurman R, Pater JM, Florquin S, Goldman M, Jansen HM, Lutter R, van der Poll T. 2004. IL-10 is an important mediator of the enhanced susceptibility to pneumococcal pneumonia after influenza infection. *J Immunol* 172:7603–7609. <https://doi.org/10.4049/jimmunol.172.12.7603>.
- Shahangian A, Chow EK, Tian X, Kang JR, Ghaffari A, Liu SY, Belperio JA, Cheng G, Deng JC. 2009. Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. *J Clin Invest* 119:1910–1920. <https://doi.org/10.1172/JCI35412>.
- Kudva A, Scheller EV, Robinson KM, Crowe CR, Choi SM, Slight SR, Khader SA, Dubin PJ, Enelow RI, Kolls JK, Alcorn JF. 2011. Influenza A inhibits Th17-mediated host defense against bacterial pneumonia in mice. *J Immunol* 186:1666–1674. <https://doi.org/10.4049/jimmunol.1002194>.
- Nakamura S, Davis KM, Weiser JN. 2011. Synergistic stimulation of type I interferons during influenza virus coinfection promotes *Streptococcus pneumoniae* colonization in mice. *J Clin Invest* 121:3657–3665. <https://doi.org/10.1172/JCI57762>.
- Li W, Moltedo B, Moran TM. 2012. Type I interferon induction during influenza virus infection increases susceptibility to secondary *Streptococcus pneumoniae* infection by negative regulation of gammadelta T cells. *J Virol* 86:12304–12312. <https://doi.org/10.1128/JVI.01269-12>.
- Sun K, Metzger DW. 2014. Influenza infection suppresses NADPH oxidase-dependent phagocytic bacterial clearance and enhances susceptibility to secondary methicillin-resistant *Staphylococcus aureus* infection. *J Immunol* 192:3301–3307. <https://doi.org/10.4049/jimmunol.1303049>.
- Gilca R, De Serres G, Boulianne N, Ouhoumane N, Papenburg J, Douville-Fradet M, Fortin E, Dionne M, Boivin G, Skowronski DM. 2011. Risk factors for hospitalization and severe outcomes of 2009 pandemic H1N1 influenza in Quebec, Canada. *Influenza Other Respir Viruses* 5:247–255. <https://doi.org/10.1111/j.1750-2659.2011.00204.x>.
- Myles P, Nguyen-Van-Tam JS, Semple MG, Brett SJ, Bannister B, Read RC, Taylor BL, McMenamin J, Enstone JE, Nicholson KG, Openshaw PJ, Lim WS, Influenza Clinical Information Network FLU-CIN. 2013. Differences between asthmatics and nonasthmatics hospitalised with influenza A infection. *Eur Respir J* 41:824–831. <https://doi.org/10.1183/09031936.00015512>.
- Louie JK, Acosta M, Samuel MC, Schechter R, Vugia DJ, Harriman K, Matyas BT, California Pandemic (H1N1) Working Group. 2011. A novel risk factor for a novel virus: obesity and 2009 pandemic influenza A (H1N1). *Clin Infect Dis* 52:301–312. <https://doi.org/10.1093/cid/ciq152>.
- Furuya Y, Furuya AK, Roberts S, Sanfilippo AM, Salmon SL, Metzger DW. 2015. Prevention of influenza virus-induced immunopathology by TGF-beta produced during allergic asthma. *PLoS Pathog* 11:e1005180. <https://doi.org/10.1371/journal.ppat.1005180>.
- Furuya Y, Roberts S, Hurteau GJ, Sanfilippo AM, Racine R, Metzger DW. 2014. Asthma increases susceptibility to heterologous but not homologous secondary influenza. *J Virol* 88:9166–9181. <https://doi.org/10.1128/JVI.00265-14>.
- Sun K, Ye J, Perez DR, Metzger DW. 2011. Seasonal FluMist vaccination induces cross-reactive T cell immunity against H1N1 (2009) influenza and secondary bacterial infections. *J Immunol* 186:987–993. <https://doi.org/10.4049/jimmunol.1002664>.
- Califano D, Furuya Y, Metzger DW. 2018. Effects of influenza on alveolar macrophage viability are dependent on mouse genetic strain. *J Immunol* 201:134–144. <https://doi.org/10.4049/jimmunol.1701406>.
- Sun K, Yajjala VK, Bauer C, Talmon GA, Fischer KJ, Kielian T, Metzger DW. 2016. Nox2-derived oxidative stress results in inefficacy of antibiotics against post-influenza *S. aureus* pneumonia. *J Exp Med* 213:1851–1864. <https://doi.org/10.1084/jem.20150514>.
- Ellis GT, Davidson S, Crotta S, Branzk N, Papayannopoulos V, Wack A. 2015. TRAIL+ monocytes and monocyte-related cells cause lung damage and thereby increase susceptibility to influenza-*Streptococcus pneumoniae* coinfection. *EMBO Rep* 16:1203–1218. <https://doi.org/10.15252/embr.201540473>.
- Jamieson AM, Yu S, Annicelli CH, Medzhitov R. 2010. Influenza virus-induced glucocorticoids compromise innate host defense against a secondary bacterial infection. *Cell Host Microbe* 7:103–114. <https://doi.org/10.1016/j.chom.2010.01.010>.
- Fahy JV. 2015. Type 2 inflammation in asthma—present in most, absent in many. *Nat Rev Immunol* 15:57–65. <https://doi.org/10.1038/nri3786>.
- Chang YJ, Kim HY, Albacker LA, Baumgarth N, McKenzie AN, Smith DE, Dekruyff RH, Umetsu DT. 2011. Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity. *Nat Immunol* 12:631–638. <https://doi.org/10.1038/ni.2045>.
- Duvigneau S, Sharma-Chawla N, Boianelli A, Stegemann-Koniszewski S, Nguyen VK, Bruder D, Hernandez-Vargas EA. 2016. Hierarchical effects of pro-inflammatory cytokines on the post-influenza susceptibility to pneumococcal coinfection. *Sci Rep* 6:37045. <https://doi.org/10.1038/srep37045>.
- Robinson KM, Lee B, Scheller EV, Mandalapu S, Enelow RI, Kolls JK, Alcorn JF. 2015. The role of IL-27 in susceptibility to post-influenza *Staphylococcus aureus* pneumonia. *Respir Res* 16:10. <https://doi.org/10.1186/s12931-015-0168-8>.
- Rynda-Apple A, Harmsen A, Erickson AS, Larson K, Morton RV, Richert LE, Harmsen AG. 2014. Regulation of IFN-gamma by IL-13 dictates susceptibility to secondary postinfluenza MRSA pneumonia. *Eur J Immunol* 44:3263–3272. <https://doi.org/10.1002/eji.201444582>.
- Breslow-Deckman JM, Mattingly CM, Birket SE, Hoskins SN, Ho TN, Garvy BA, Feola DJ. 2013. Linezolid decreases susceptibility to secondary bacterial pneumonia postinfluenza infection in mice through its effects on IFN-gamma. *J Immunol* 191:1792–1799. <https://doi.org/10.4049/jimmunol.1300180>.
- Hang DTT, Choi EJ, Song JY, Kim SE, Kwak J, Shin YK. 2011. Differential effect of prior influenza infection on alveolar macrophage phagocytosis of *Staphylococcus aureus* and *Escherichia coli*: involvement of interferon-gamma production. *Microbiol Immunol* 55:751–759. <https://doi.org/10.1111/j.1348-0421.2011.00383.x>.
- Sun K, Gan Y, Metzger DW. 2011. Analysis of murine genetic predisposition to pneumococcal infection reveals a critical role of alveolar macrophages in maintaining the sterility of the lower respiratory tract. *Infect Immun* 79:1842–1847. <https://doi.org/10.1128/IAI.01143-10>.
- Sanfilippo AM, Furuya Y, Roberts S, Salmon SL, Metzger DW. 2015. Allergic lung inflammation reduces tissue invasion and enhances survival from pulmonary pneumococcal infection in mice, which correlates with increased expression of transforming growth factor beta1 and SiglecF(low) alveolar macrophages. *Infect Immun* 83:2976–2983. <https://doi.org/10.1128/IAI.00142-15>.
- Lykens JE, Terrell CE, Zoller EE, Divanovic S, Trompette A, Karp CL, Aliberti J, Flick MJ, Jordan MB. 2010. Mice with a selective impairment of IFN-gamma signaling in macrophage lineage cells demonstrate the critical role of IFN-gamma-activated macrophages for the control of protozoan parasitic infections in vivo. *J Immunol* 184:877–885. <https://doi.org/10.4049/jimmunol.0902346>.
- Stahl PD, Ezekowitz RA. 1998. The mannose receptor is a pattern recognition receptor involved in host defense. *Curr Opin Immunol* 10:50–55. [https://doi.org/10.1016/S0952-7915\(98\)80031-9](https://doi.org/10.1016/S0952-7915(98)80031-9).
- Li N, Ren A, Wang X, Fan X, Zhao Y, Gao GF, Cleary P, Wang B. 2015. Influenza viral neuraminidase primes bacterial coinfection through TGF-

- beta-mediated expression of host cell receptors. *Proc Natl Acad Sci U S A* 112:238–243. <https://doi.org/10.1073/pnas.1414422112>.
33. Carlson CM, Turpin EA, Moser LA, O'Brien KB, Cline TD, Jones JC, Tumpey TM, Katz JM, Kelley LA, Gauldie J, Schultz-Cherry S. 2010. Transforming growth factor-beta: activation by neuraminidase and role in highly pathogenic H5N1 influenza pathogenesis. *PLoS Pathog* 6:e1001136. <https://doi.org/10.1371/journal.ppat.1001136>.
 34. Dutta A, Huang CT, Chen TC, Lin CY, Chiu CH, Lin YC, Chang CS, He YC. 2015. IL-10 inhibits neuraminidase-activated TGF-beta and facilitates Th1 phenotype during early phase of infection. *Nat Commun* 6:6374. <https://doi.org/10.1038/ncomms7374>.
 35. Schultz-Cherry S, Hinshaw VS. 1996. Influenza virus neuraminidase activates latent transforming growth factor beta. *J Virol* 70:8624–8629.
 36. Gratz N, Loh LN, Mann B, Gao G, Carter R, Rosch J, Tuomanen EI. 2017. Pneumococcal neuraminidase activates TGF-beta signalling. *Microbiology* 163:1198–1207. <https://doi.org/10.1099/mic.0.000511>.
 37. Halwani R, Al-Muhsen S, Al-Jahdali H, Hamid Q. 2011. Role of transforming growth factor-beta in airway remodeling in asthma. *Am J Respir Cell Mol Biol* 44:127–133. <https://doi.org/10.1165/rcmb.2010-0027TR>.
 38. Batra V, Musani AI, Hastie AT, Khurana S, Carpenter KA, Zangrilli JG, Peters SP. 2004. Bronchoalveolar lavage fluid concentrations of transforming growth factor (TGF)-beta1, TGF-beta2, interleukin (IL)-4 and IL-13 after segmental allergen challenge and their effects on alpha-smooth muscle actin and collagen III synthesis by primary human lung fibroblasts. *Clin Exp Allergy* 34:437–444. <https://doi.org/10.1111/j.1365-2222.2004.01885.x>.
 39. Avila PC, Abisheganaden JA, Wong H, Liu J, Yagi S, Schnurr D, Kishiyama JL, Boushey HA. 2000. Effects of allergic inflammation of the nasal mucosa on the severity of rhinovirus 16 cold. *J Allergy Clin Immunol* 105:923–932. <https://doi.org/10.1067/mai.2000.106214>.
 40. Samarasinghe AE, Woolard SN, Boyd KL, Hoselton SA, Schuh JM, McCullers JA. 2014. The immune profile associated with acute allergic asthma accelerates clearance of influenza virus. *Immunol Cell Biol* 92:449–459. <https://doi.org/10.1038/icb.2013.113>.
 41. Ishikawa H, Sasaki H, Fukui T, Fujita K, Kutsukake E, Matsumoto T. 2012. Mice with asthma are more resistant to influenza virus infection and NK cells activated by the induction of asthma have potentially protective effects. *J Clin Immunol* 32:256–267. <https://doi.org/10.1007/s10875-011-9619-2>.
 42. Kawaguchi A, Suzuki T, Ohara Y, Takahashi K, Sato Y, Aina A, Nagata N, Tashiro M, Hasegawa H. 2017. Impacts of allergic airway inflammation on lung pathology in a mouse model of influenza A virus infection. *PLoS One* 12:e0173008. <https://doi.org/10.1371/journal.pone.0173008>.
 43. Lee DCP, Tay NQ, Thian M, Prabhu N, Furuhashi K, Kemeny DM. 2018. Prior exposure to inhaled allergen enhances anti-viral immunity and T cell priming by dendritic cells. *PLoS One* 13:e0190063. <https://doi.org/10.1371/journal.pone.0190063>.
 44. An S, Jeon YJ, Jo A, Lim HJ, Han YE, Cho SW, Kim HY, Kim HJ. 2018. Initial influenza virus replication can be limited in allergic asthma through rapid induction of type III interferons in respiratory epithelium. *Front Immunol* 9:986. <https://doi.org/10.3389/fimmu.2018.00986>.
 45. Nicholas B, Dudley S, Tariq K, Howarth P, Lunn K, Pink S, Sterk PJ, Adcock IM, Monk P, Djukanovic R, U-BIOPRED Study Group. 2017. Susceptibility to influenza virus infection of bronchial biopsies in asthma. *J Allergy Clin Immunol* 140:309.e4–312.e4. <https://doi.org/10.1016/j.jaci.2016.12.964>.
 46. Nakamura S, Yaguchi T, Kawamura N, Kobayashi A, Sakurai T, Higuchi H, Takaishi H, Hibi T, Kawakami Y. 2014. TGF-beta1 in tumor microenvironments induces immunosuppression in the tumors and sentinel lymph nodes and promotes tumor progression. *J Immunother* 37:63–72. <https://doi.org/10.1097/CJI.0000000000000011>.
 47. Vanpouille-Box C, Diamond JM, Pilonis KA, Zavadil J, Babb JS, Formenti SC, Barcellos-Hoff MH, Demaria S. 2015. TGFbeta is a master regulator of radiation therapy-induced antitumor immunity. *Cancer Res* 75:2232–2242. <https://doi.org/10.1158/0008-5472.CAN-14-3511>.
 48. Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE, III, Koepfen H, Asterita JL, Cubas R, Jhunjhunwala S, Banachereau R, Yang Y, Guan Y, Chalouni C, Ziai J, Şenbabaoğlu Y, Santoro S, Sheinson D, Hung J, Giltner JM, Pierce AA, Mesh K, Lianoglou S, Riegler J, Carano RAD, Eriksson P, Höglund M, Somarriba L, Halligan DL, van der Heijden MS, Loriot Y, Rosenberg JE, Fong L, Mellman I, Chen DS, Green M, Derleth C, Fine GD, Hegde PS, Bourgon R, Powles T. 2018. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. *Nature* 554:544–548. <https://doi.org/10.1038/nature25501>.
 49. Tauriello DVF, Palomo-Ponce S, Stork D, Berenguer-Llargo A, Badia-Ramentol J, Iglesias M, Sevillano M, Ibiza S, Canellas A, Hernando-Mombona X, Byrom D, Matarin JA, Calon A, Rivas EI, Nebreda AR, Riera A, Attolini CS, Batlle E. 2018. TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis. *Nature* 554:538–543. <https://doi.org/10.1038/nature25492>.
 50. Li MO, Flavell RA. 2008. TGF-beta: a master of all T cell trades. *Cell* 134:392–404. <https://doi.org/10.1016/j.cell.2008.07.025>.
 51. Veerapandian R, Snyder JD, Samarasinghe AE. 2018. Influenza in asthmatics: for better or for worse? *Front Immunol* 9:1843. <https://doi.org/10.3389/fimmu.2018.01843>.
 52. Van Kerkhove MD, Vandemaële KA, Shinde V, Jaramillo-Gutierrez G, Koukounari A, Donnelly CA, Carlino LO, Owen R, Paterson B, Pelletier L, Vachon J, Gonzalez C, Hongjie Y, Zijian F, Chuang SK, Au A, Buda S, Krause G, Haas W, Bonmarin I, Taniguchi K, Nakajima K, Shobayashi T, Takayama Y, Sunagawa T, Heraud JM, Orelle A, Palacios E, van der Sande MA, Wielders CC, Hunt D, Cutter J, Lee VJ, Thomas J, Santa-Olalla P, Sierra-Moros MJ, Hanshaworakul W, Ungchusak K, Pebody R, Jain S, Mounts AW, WHO Working Group for Risk Factors for Severe H1N1pdm Infection. 2011. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis. *PLoS Med* 8:e1001053. <https://doi.org/10.1371/journal.pmed.1001053>.
 53. Bramley AM, Dasgupta S, Skarbinski J, Kamimoto L, Fry AM, Finelli L, Jain S, 2009 Pandemic Influenza A (H1N1) Virus Hospitalizations Investigation Team. 2012. Intensive care unit patients with 2009 pandemic influenza A (H1N1pdm09) virus infection—United States, 2009. *Influenza Other Respir Viruses* 6:e134–e142. <https://doi.org/10.1111/j.1750-2659.2012.00385.x>.
 54. Eriksson CO, Graham DA, Uyeki TM, Randolph AG. 2012. Risk factors for mechanical ventilation in U.S. children hospitalized with seasonal influenza and 2009 pandemic influenza A*. *Pediatr Crit Care Med* 13:625–631. <https://doi.org/10.1097/PCC.0b013e318260114e>.
 55. von der Beck D, Seeger W, Herold S, Günther A, Löh B. 2017. Characteristics and outcomes of a cohort hospitalized for pandemic and seasonal influenza in Germany based on nationwide inpatient data. *PLoS One* 12:e0180920. <https://doi.org/10.1371/journal.pone.0180920>.
 56. McKenna JJ, Bramley AM, Skarbinski J, Fry AM, Finelli L, Jain S, 2009 Pandemic Influenza A (H1N1) Virus Hospitalizations Investigation Team. 2013. Asthma in patients hospitalized with pandemic influenza A(H1N1)pdm09 virus infection—United States, 2009. *BMC Infect Dis* 13:57. <https://doi.org/10.1186/1471-2334-13-57>.
 57. Louis JK, Acosta M, Winter K, Jean C, Gavali S, Schechter R, Vugia D, Harriman K, Matyas B, Glaser CA, Samuel MC, Rosenberg J, Talarico J, Hatch D, California Pandemic Working Group. 2009. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. *JAMA* 302:1896–1902. <https://doi.org/10.1001/jama.2009.1583>.
 58. Nguyen-Van-Tam JS, Openshaw PJ, Hashim A, Gadd EM, Lim WS, Semple MG, Read RC, Taylor BL, Brett SJ, McMenamin J, Enstone JE, Armstrong C, Nicholson KG, Influenza Clinical Information Network (FLU-CIN). 2010. Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May–September 2009). *Thorax* 65:645–651. <https://doi.org/10.1136/thx.2010.135210>.
 59. Myles PR, Semple MG, Lim WS, Openshaw PJ, Gadd EM, Read RC, Taylor BL, Brett SJ, McMenamin J, Enstone JE, Armstrong C, Bannister B, Nicholson KG, Nguyen-Van-Tam JS, Influenza Clinical Information Network (FLU-CIN). 2012. Predictors of clinical outcome in a national hospitalised cohort across both waves of the influenza A/H1N1 pandemic 2009–2010 in the UK. *Thorax* 67:709–717. <https://doi.org/10.1136/thoraxjnl-2011-200266>.
 60. Weinberger DM, Simonsen L, Jordan R, Steiner C, Miller M, Viboud C. 2012. Impact of the 2009 influenza pandemic on pneumococcal pneumonia hospitalizations in the United States. *J Infect Dis* 205:458–465. <https://doi.org/10.1093/infdis/jir749>.
 61. Gill JR, Sheng ZM, Ely SF, Guinee DG, Beasley MB, Suh J, Deshpande C, Mollura DJ, Morens DM, Bray M, Travis WD, Taubenberger JK. 2010. Pulmonary pathologic findings of fatal 2009 pandemic influenza A/H1N1 viral infections. *Arch Pathol Lab Med* 134:235–243. <https://doi.org/10.1043/1543-2165-134.2.235>.
 62. Centers for Disease Control and Prevention. 2009. Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1)—United States, May–August 2009. *MMWR Morb Mortal Wkly Rep* 58:1071–1074.
 63. Kloepfer KM, Lee WM, Pappas TE, Kang TJ, Vrtis RF, Evans MD, Gangnon RE, Bochkov YA, Jackson DJ, Lemanske RF, Jr, Gern JE. 2014. Detection of

- pathogenic bacteria during rhinovirus infection is associated with increased respiratory symptoms and asthma exacerbations. *J Allergy Clin Immunol* 133:1301–1307, 1307.e1–1307.e3. <https://doi.org/10.1016/j.jaci.2014.02.030>.
64. Zhang Y, Sun W, Svendsen ER, Tang S, MacIntyre RC, Yang P, Zhang D, Wang Q. 2015. Do corticosteroids reduce the mortality of influenza A (H1N1) infection? A meta-analysis. *Crit Care* 19:46. <https://doi.org/10.1186/s13054-015-0764-5>.
 65. Lansbury L, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. 2019. Corticosteroids as adjunctive therapy in the treatment of influenza. *Cochrane Database Syst Rev* 2:CD010406. <https://doi.org/10.1002/14651858.CD010406.pub3>.
 66. Lee N, Leo YS, Cao B, Chan PK, Kyaw WM, Uyeki TM, Tam WW, Cheung CS, Yung IM, Li H, Gu L, Liu Y, Liu Z, Qu J, Hui DS. 2015. Neuraminidase inhibitors, superinfection and corticosteroids affect survival of influenza patients. *Eur Respir J* 45:1642–1652. <https://doi.org/10.1183/09031936.00169714>.
 67. Brun-Buisson C, Richard J-CM, Mercat A, Thiébaud ACM, Brochard L, REVA-SRLF A/H1N1v 2009 Registry Group. 2011. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. *Am J Respir Crit Care Med* 183:1200–1206. <https://doi.org/10.1164/rccm.201101-0135OC>.
 68. Aun MV, Bonamichi-Santos R, Arantes-Costa FM, Kalil J, Giavina-Bianchi P. 2017. Animal models of asthma: utility and limitations. *J Asthma Allergy* 10:293–301. <https://doi.org/10.2147/JAA.S121092>.
 69. Kumar RK, Foster PS. 2012. Are mouse models of asthma appropriate for investigating the pathogenesis of airway hyper-responsiveness? *Front Physiol* 3:312. <https://doi.org/10.3389/fphys.2012.00312>.
 70. Temelkovski J, Hogan SP, Shepherd DP, Foster PS, Kumar RK. 1998. An improved murine model of asthma: selective airway inflammation, epithelial lesions and increased methacholine responsiveness following chronic exposure to aerosolised allergen. *Thorax* 53:849–856. <https://doi.org/10.1136/thx.53.10.849>.
 71. Kumar RK, Herbert C, Yang M, Koskinen AM, McKenzie AN, Foster PS. 2002. Role of interleukin-13 in eosinophil accumulation and airway remodelling in a mouse model of chronic asthma. *Clin Exp Allergy* 32:1104–1111. <https://doi.org/10.1046/j.1365-2222.2002.01420.x>.
 72. Johnson JR, Wiley RE, Fattouh R, Swirski FK, Gajewska BU, Coyle AJ, Gutierrez-Ramos JC, Ellis R, Inman MD, Jordana M. 2004. Continuous exposure to house dust mite elicits chronic airway inflammation and structural remodeling. *Am J Respir Crit Care Med* 169:378–385. <https://doi.org/10.1164/rccm.200308-1094OC>.
 73. Kumar RK, Herbert C, Webb DC, Li L, Foster PS. 2004. Effects of anticytokine therapy in a mouse model of chronic asthma. *Am J Respir Crit Care Med* 170:1043–1048. <https://doi.org/10.1164/rccm.200405-681OC>.
 74. Sykes A, Edwards MR, Macintyre J, del Rosario A, Bakhsholiani E, Trujillo-Torralbo MB, Kon OM, Mallia P, McHale M, Johnston SL. 2012. Rhinovirus 16-induced IFN-alpha and IFN-beta are deficient in bronchoalveolar lavage cells in asthmatic patients. *J Allergy Clin Immunol* 129:1506.e6–1514.e6. <https://doi.org/10.1016/j.jaci.2012.03.044>.
 75. Baraldo S, Contoli M, Bazzan E, Turato G, Padovani A, Marku B, Calabrese F, Caramori G, Ballarin A, Srijders D, Barbato A, Saetta M, Papi A. 2012. Deficient antiviral immune responses in childhood: distinct roles of atopy and asthma. *J Allergy Clin Immunol* 130:1307–1314. <https://doi.org/10.1016/j.jaci.2012.08.005>.
 76. Gill MA, Bajwa G, George TA, Dong CC, Dougherty II, Jiang N, Gan VN, Gruchalla RS. 2010. Counterregulation between the FcepsilonRI pathway and antiviral responses in human plasmacytoid dendritic cells. *J Immunol* 184:5999–6006. <https://doi.org/10.4049/jimmunol.0901194>.
 77. Rupani H, Martinez-Nunez RT, Dennison P, Lau LC, Jayasekera N, Have-lock T, Francisco-Garcia AS, Grainge C, Howarth PH, Sanchez-Elsner T. 2016. Toll-like receptor 7 is reduced in severe asthma and linked to an altered microRNA profile. *Am J Respir Crit Care Med* 194:26–37. <https://doi.org/10.1164/rccm.201502-0280OC>.
 78. Bosch AA, Biesbroek G, Trzcinski K, Sanders EA, Bogaert D. 2013. Viral and bacterial interactions in the upper respiratory tract. *PLoS Pathog* 9:e1003057. <https://doi.org/10.1371/journal.ppat.1003057>.
 79. Jamieson AM, Pisman L, Yu S, Gamradt P, Homer RJ, Decker T, Medzhitov R. 2013. Role of tissue protection in lethal respiratory viral-bacterial coinfection. *Science* 340:1230–1234. <https://doi.org/10.1126/science.1233632>.
 80. Wong SM, Bernui M, Shen H, Akerley BJ. 2013. Genome-wide fitness profiling reveals adaptations required by *Haemophilus* in coinfection with influenza A virus in the murine lung. *Proc Natl Acad Sci U S A* 110:15413–15418. <https://doi.org/10.1073/pnas.1311217110>.
 81. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.